Lilly’s anticancer abemaciclib and rheumatoid arthritis drug baricitinib, which has received a US EUA for COVID-19, have become targets of challenger Natco in India. The US giant says it's working closely with India’s health ministry to ensure access to patients who need its innovative therapies, amid indications Natco may be weighing plans to seek a voluntary license for baricitinib.
Lilly Will Need To Fend Off Challenge To Some Products In India • Source: Shutterstock
Eli Lilly and Company is at loggerheads with Natco Pharma Limited in India over intellectual property rights issues pertaining to the US firm’s breast cancer drug abemaciclib, while its JAK inhibitor baricitinib (sold as Olumiant) is also on the challenger’s radar.
Lilly and Natco are locked in a legal battle concerning CDK4/6 inhibitor abemaciclib (available as Verzenio internationally), while the Indian...
